LncRNA SNHG17 Promotes Tumor Progression and Predicts Poor Survival in Human Renal Cell Carcinoma via Sponging miR-328-3p

Abstract

Background: Accumulating data shows that dysregulation of long non-coding RNAs (lncRNAs) are involved in human tumors' occurrence and progression. Small nucleolar RNA host genes (SNHGs) are recently revealed to play a carcinogenic role in various human neoplasms. However, the functions and underlying mechanisms of lncRNA SNHG17 in renal cell carcinoma (RCC) are still elusive.Methods: We analyzed the relationship between SNHG17 expression levels and clinicopathologic characteristics and prognosis in patients with RCC according to TCGA RNA-sequencing data and our cohort data. Loss-of-function and gain-of-function experiments were conducted to examine the biological behaviors of SNHG17 on RCC cell proliferation, migration, invasion, apoptosis, and tumor growth in vivo. The interaction between SNHG17, miR-328-3p, and Histone’s H2A variant (H2AX) was verified by bioinformatics, dual-luciferase reporter gene, and RNA immunoprecipitation (RIP). Results: Highly expressed SNHG17 was evident in RCC tissue samples and cell lines, and SNHG17 overexpression was related to advanced TNM stage and reduced relapse-free and overall survival of patients with RCC. Knockdown of SNHG17 prohibited malignant phenotypes, whereas ectopic SNHG17 expression showed the opposite effects. More importantly, SNHG17 could upregulate the expression of H2AX by acting as a miR-328-3p sponge. In vivo experiments confirmed that SNHG17 promoted the growth of RCC tumors.Conclusion: SNHG17/miR-328-3p/H2AX axis might be involved in RCC progression, which provided a potential therapeutic target for RCC.

Integrative Analysis and Experimental Validation Indicated That SNHG17 Is a Prognostic Marker in Prostate Cancer and a Modulator of the Tumor Microenvironment via a Competitive Endogenous RNA Regulatory Network

“…Additionally, we observed that the expression of SNHG17, UBE2M, and OTUB1 was significantly correlated with a decreased infiltrating level of immune cells, indicating the immunological role of SNHG17 and its ceRNA regulatory network in prostate cancer. It has been widely recognized that SNGH17 functions as an oncogene in many cancers, such as non-small-cell lung cancer (NSCLC) [32], breast cancer (BC) [33], gastric cancer (GC) [23], and renal cell carcinoma (RCC) [34]. The tumorigenesis function and related mechanisms of SNHG17 in driving prostate cancer have also been studied.…”

Identification and Validation of Lipid Metabolism-Related LncRNA Prognostic Signature for Patients with Osteosarcoma

“…A large number of studies have also shown that SNHG17 plays an important pathogenic role in a variety of tumor-associated diseases. Such as SNHG17 can upregulated PAX6 to exert its carcinogenic role acted as a ceRNA of miR-375 [30], promoting epithelial-mesenchymal transition (EMT) progress, proliferation and invasion of ESCC cells by sponging miR-338-3p, thereby activating SOX4 [31], and may regulate H2AX signaling via miR-328-3p in renal cell carcinoma [32]. In summary, numerous evidences indicate that SNHG17 plays an important role in tumor development and has important clinical application value in tumor diagnosis and prognosis.…”